COST-EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Taheri, S. [1 ]
Motevalli, M. H. [1 ]
Peiravian, F. [1 ]
Yousefi, N. [1 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacoecon & Pharma Management, Tehran, Iran
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN168
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [31] Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Lin, Yuxuan
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [32] Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
    Zou, Huimin
    Lai, Yunfeng
    Chen, Xianwen
    Ung, Carolina Oi Lam
    Hu, Hao
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [33] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [34] Cost-effectiveness of regorafenib in the treatment of advanced hepatocellular carcinoma in Canada
    Hussain, Salman
    Singh, Ambrish
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 382 - 382
  • [35] A systematic review of cost-effectiveness analyses for the treatment of stroke
    Holloway, RG
    Benesch, C
    Courtright, CE
    Rahilly, CR
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 517 - 517
  • [36] Cost-Effectiveness of Glucosamine in Osteoarthritis Treatment: A Systematic Review
    Vo, Nam Xuan
    Le, Ngan Nguyen Hoang
    Chu, Trinh Dang Phuong
    Pham, Huong Lai
    Dinh, Khang Xuan An
    Che, Uyen Thi Thuc
    Ngo, Thanh Thi Thanh
    Bui, Tien Thuy
    HEALTHCARE, 2023, 11 (16)
  • [37] Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis
    Sasse, A.
    Carmo, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
  • [38] Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
    Shuling Chen
    Zhenwei Peng
    Mengchao Wei
    Weifeng Liu
    Zihao Dai
    Haibo Wang
    Jie Mei
    Mingfong Cheong
    Hanmei Zhang
    Ming Kuang
    BMC Cancer, 18
  • [39] ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN
    Ikeda, S.
    Kudo, M.
    Izumi, N.
    Kaneko, S.
    Kobayashi, M.
    Azuma, M.
    Copher, R.
    Virabhak, S.
    Mitchell, D.
    Meier, G.
    Ishii, M.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [40] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
12345